OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2-advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors

被引：0
|
作者：
Pistilli, Barbara
Bellet, Meritxell
Del Mastro, Lucia
McArthur, Heather L.
Meisel, Jane Lowe
Schmid, Peter
Sohn, Joohyuk
De Kermadec, Elisabeth
Wei, Rachel
Chan, Arlene
机构：
[1] Gustave Roussy, Villejuif, France
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Vall Hebron Inst Oncol, Barcelona, Spain
[4] IRCCS Osped Policlinico San Martino Genoa, Dept Clin Oncol, Genoa, Italy
[5] UT SouthWestern Med Ctr, Dallas, TX USA
[6] Emory Univ, Winship Canter Inst, Atlanta, GA USA
[7] Queen Mary Univ London, Barts Canc Inst, London, England
[8] Yonsei Univ, Div Med Oncol, Dept Internal Med, Coll Med, Seoul, South Korea
[9] Olema Oncol, San Francisco, CA USA
[10] Breast Canc Res Ctr WA, Nedlands, WA, Australia
[11] Curtin Univ, Nedlands, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1135
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR+/HER2-advanced breast cancer after CDK4/6 inhibitors: Preliminary findings of a multi-center, phase II study
    Zheng, Q.
    Zhou, H.
    Wu, H-L.
    Cai, Y.
    Chen, L-M.
    Huang, J.
    Hong, R.
    Xia, W.
    Jiang, K.
    Xu, F.
    Wang, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S372 - S372
  • [22] Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2-metastatic breast cancer (Chloe trial)
    Shien, T.
    Shimomura, A.
    Uemura, Y.
    Kato, H.
    Kitada, M.
    Kikawa, Y.
    Shiba, E.
    Yoshida, T.
    Morimoto, T.
    Toyama, T.
    Aihara, T.
    Mukai, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Efficacy and safety of first-line therapy with fulvestrant or exemestane for postmenopausal ER+/HER2-advanced breast cancer patients after adjuvant nonsteroidal aromatase inhibitor treatment: A randomized, open-label, multicenter study
    Wang, J.
    Xu, B.
    Cai, L.
    Song, Y.
    Kang, L.
    Sun, T.
    Teng, Y.
    Tong, Z.
    Li, H.
    Ouyang, Q.
    Cui, S.
    Yan, M.
    Chen, Q.
    Yin, Y.
    Sun, Q.
    Liao, N.
    Feng, J.
    Wang, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S461 - S462
  • [24] A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients
    Chan, Arlene
    Day, Daphne
    Phuong Dinh
    Slancar, Michael
    Lombard, Janine
    Ganju, Vinod
    McCarthy, Nicole
    Wilson, Rosalind
    Faltaos, Demiana
    Mathauda-Sahota, Gurpreet
    Murphy, Caitlin
    CANCER RESEARCH, 2024, 84 (09)
  • [25] A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer
    Borges, Virginia F.
    Chan, Arlene
    Lin, Nancy U.
    Tonda, Margaret Eleanor
    Shilkrut, Mark
    Alemany, Carlos A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET)
    Kaklamani, Virginia G.
    Bidard, Francois Clement
    Neven, Patrick
    Montero, Alberto J.
    Mouret-Reynier, Marie-Ange
    Sohn, Joohyuk
    Taylor, Donatienne
    Forget, Frederic
    Harnden, Kathleen Kiernan
    Khong, Hung T.
    Kocsis, Judit
    Dalenc, Florence
    Dillon, Patrick Michael
    Waters, Simon
    Garcia-Saenz, Jose A.
    Aftimos, Philippe Georges
    Cortes, Javier
    Scartoni, Simona
    Habboubi, Nassir
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] TWT-203: Phase 1b/2 dose-confirming study of CFI-402257 as a single agent in advanced solid tumors and in combination with fulvestrant in patients with ER+/ HER2-advanced breast cancer after disease progression on prior CDK4/6 and endocrine therapy
    Wesolowski, Robert
    Bray, Mark R.
    Michelson, Glenn C.
    Roberts-Thomson, Emily L.
    Denny, Trisha
    Cescon, David W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2-metastatic breast cancer.
    Mayer, Erica L.
    Wander, Seth Andrew
    Regan, Meredith M.
    DeMichele, Angela
    Forero-Torres, Andres
    Rimawi, Mothaffar F.
    Ma, Cynthia X.
    Cristofanilli, Massimo
    Anders, Carey K.
    Bartlett, Cynthia Huang
    Winer, Eric P.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Systematic review and meta-analysis of post-progression outcomes in ER+/HER2-metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
    Munzone, E.
    Pagan, E.
    Bagnardi, V
    Montagna, E.
    Cancello, G.
    Dellapasqua, S.
    Iorfida, M.
    Mazza, M.
    Colleoni, M.
    ESMO OPEN, 2021, 6 (06)
  • [30] Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2-breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors
    Goetz, M. P.
    Plourde, P.
    Stover, D. G.
    Bagegni, N.
    Vidal, G. A.
    Brufsky, A.
    Rugo, H. S.
    Portman, D. J.
    Gal-Yam, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1387 - S1388
12345